Across industries, senior leaders are facing a workforce challenge driven by increasingly specialized business demands. Technology, finance, manufacturing, and healthcare can all require highly specific expertise for initiatives that may last several months or apply only to one stage of a broader transformation. Traditional talent structures, built around permanent positions and defined responsibilities, can make it challenging to align specialized capabilities with rapidly shifting priorities.
This tension becomes particularly apparent when a new regulatory requirement, technology, product milestone, or strategic initiative creates an immediate need for expertise. Executive hiring can take months, while the business need itself may exist for a much shorter period. This has contributed to growing interest in fractional leadership, where experienced executives provide specialized capabilities for defined periods or specific organizational needs.
Pharmaceuticals offer a particularly relevant example because scientific complexity, regulatory requirements, and stakeholder expectations continue to evolve at the same time. Within this environment, Medical Affairs demonstrates how an organization may need highly specialized leadership at specific stages of a product’s development without necessarily requiring those same capabilities throughout the entire lifecycle.
Medical Affairs remains less familiar to many people outside the pharmaceutical industry than functions such as R&D or commercial operations. Its responsibilities, however, occupy an important scientific role within pharmaceutical organizations. Medical Affairs professionals facilitate scientific exchange with healthcare professionals, interpret and communicate evidence, support evidence-generation activities, and help connect emerging scientific knowledge with the needs of clinicians and patients. The distinction between scientific exchange and promotional activity is also particularly important in a highly regulated environment, where pharmaceutical communications must comply with applicable FDA requirements.
Michelle Chernock, PhD, founder of Leaders in Medical Affairs, a Medical Affairs consulting firm serving pharmaceutical, biotechnology, and medical device organizations, has more than two decades of experience working across startup and global pharmaceutical environments. Her perspective highlights a recurring leadership challenge. “Organizations can have an established Medical Affairs function while still encountering a specialized capability gap at a particular point in development, launch, or therapeutic-area expansion,” she notes.
That gap can arise because Medical Affairs includes a wide range of disciplines. Teams may require expertise in compliance, physician communications, evidence interpretation and generation, external expert engagement, medical strategy, or therapeutic-area knowledge. A team member with extensive experience in one stage of development may face an entirely different set of requirements at another. Dr. Chernock’s experience suggests that the question for executives increasingly centers on how to access the right expertise for a particular business requirement and timeframe.
The broader scientific landscape reinforces that question. McKinsey’s research on Medical Affairs describes an industry experiencing expanding therapeutic options, increasingly sophisticated data, and rapidly advancing digital and analytical capabilities. Its report notes that healthcare practitioners and patients had access to 75% more assets per indication than a decade earlier, contributing to the growing volume of scientific information clinicians must navigate. McKinsey also identifies capability gaps, budget limitations, organizational alignment, and competing priorities as factors shaping the evolution of Medical Affairs.
For Dr. Chernock, this environment creates a practical opportunity for experienced fractional expertise. “A company may require senior leadership for a launch, temporary leave coverage, a therapeutic-area expansion, an unusually demanding workload, or a specific capability that has yet to be developed internally,” she explains. “An experienced professional can contribute to a defined need while the organization determines its longer-term structure in such circumstances.”
This model also reflects a broader change in executive careers. Dr. Chernock points to similar patterns in technology, where shorter business and product cycles can generate demand for specific executive capabilities over six to 24 months. Senior professionals with decades of experience may increasingly pursue portfolio careers that allow them to apply specialized knowledge across organizations and defined periods.
The difference between fractional leadership and conventional consulting is important here. Fractional executives can become part of the leadership structure for a defined period or mandate, providing expertise and accountability alongside internal teams. This arrangement can give organizations access to senior-level knowledge when a permanent position may exceed the actual duration or scope of the requirement.
“Executives can begin identifying a Medical Affairs capability gap by asking several questions,” Dr. Chernock states. “Does the organization have the expertise required for its current development stage? Is an upcoming launch creating a temporary increase in complexity? Does a therapeutic expansion require knowledge that the existing team has limited exposure to? Could a short-term leadership requirement benefit from someone who has already navigated a comparable situation?”
These questions point toward a broader evolution in how organizations approach talent. As scientific fields become more specialized and business cycles move faster, executive capacity can increasingly be structured around the work itself, its timing, and the expertise needed to deliver it. McKinsey’s vision for Medical Affairs similarly anticipates broader skill sets, greater use of analytics and digital capabilities, and organizational models capable of adapting to changing priorities.
For pharmaceutical leaders, the lesson extends beyond staffing decisions. Medical Affairs operates within a business environment where scientific credibility, responsible communication, evidence generation, and stakeholder needs intersect with significant organizational decisions. Having access to the right expertise at the right stage can therefore become an important consideration for leadership teams.
Across industries, the emerging question may be less about maintaining a fixed executive structure and more about ensuring specialized knowledge is available when the business needs it. Fractional leadership represents one response to this shift, giving organizations another way to connect experienced expertise with periods of concentrated demand.
